+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Monoclonal Antibodies Market 2020-2026

  • ID: 5240864
  • Report
  • June 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • AbbVie, Inc.
  • Aytu BioScience, Inc.
  • Biogen, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
Global Monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Source (Murine, Chimeric, Human, and Humanized), By Application (Cancer, Infectious Diseases, Auto-Immune Diseases, Inflammatory Diseases, and Others) and Forecast, 2020-2026.

The global monoclonal antibodies market is estimated to grow at a CAGR of 8.6% during the forecast period. The market is significantly driven by the increasing prevalence of cancer and the rising focus on the development of monoclonal antibodies. As per the World Health Organization (WHO), in 2018, 18.1 million new cancer incidences were reported globally. Globally, in 2018, 43.8 million persons were suffering from cancer who were diagnosed within the last 5 years. Monoclonal antibodies are developed in laboratories and are molecular engineered to act as alternate antibodies that can restore, increase, or mimic the attack of the immune system on cancer cells. These antibodies are intended to attach to antigens that are normally multiple on the surface of cancer cells compared to healthy cells. Monoclonal antibody drugs can function in several ways, including blocking cell growth and immune system inhibitors, flagging cancer cells, delivering chemotherapy and radiation treatment, directly attacking cancer cells, and others.

The global monoclonal antibodies market is segmented based on source and application. Based on the source, the market is classified into murine, chimeric, human, and humanized. In humanized monoclonal antibodies, the antibodies are derived from non-human species. The protein sequences of these species have been altered to enhance their similarity to antibody variants manufactured naturally in humans. The humanization process is normally utilized in monoclonal antibodies that are developed for humans administration (for instance, developing antibodies as anti-cancer drugs). It is an established technique to reduce the immunogenicity of monoclonal antibodies from xenogeneic sources (usually rodent). In addition, it is used to improve the activation of the human immune system. Several humanized monoclonal antibodies have been reported in clinical trials and some have been approved to be utilized as drugs. Based on the application, the market is classified into cancer, infectious diseases, auto-immune diseases, inflammatory diseases, and others.

Geographically, the market is classified into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2019, North America held the largest share in the market owing to the rising cancer incidences and a significant rise in FDA approvals for monoclonal antibodies. As per the Centers for Disease Control and Prevention (CDC), the number of new cancer incidences in the US is expected to grow from nearly 1.5 million annually in 2010 to 1.9 million annually in 2020. This results in an increasing demand for monoclonal antibody drugs that act as a targeted therapy to destroy cancer cells.

Some prominent players in the market include Amgen Inc., Eli Lilly & Co., F- Hoffman La-Roche AG, Pfizer Inc., and Novartis AG. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in July 2020, Cadila Pharmaceuticals Ltd. declared the introduction of biosimilar Rituximab in India. It is launched within the brand name Ritucad and is indicated for the treatment of rheumatoid arthritis and blood cancer. It is used to treat Non-Hodgkin’s lymphoma (a type of blood-related cancer). According to the company, over 28,000 new cases of Lymphoma are reported each year in India. This launch will increase the accessibility of cancer treatment in the country.

Research Methodology

The market study of the global monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Monoclonal Antibodies Market Research and Analysis by Source
2. Global Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers:
  • Comprehensive research methodology of the global monoclonal antibodies market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global monoclonal antibodies market.
  • Insights about market determinants which are stimulating the global monoclonal antibodies market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie, Inc.
  • Aytu BioScience, Inc.
  • Biogen, Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules and Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Amgen Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Eli Lilly and Co.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. F. Hoffmann-La Roche AG
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Pfizer Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Novartis AG
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities

5. Market Segmentation
5.1. Global Monoclonal Antibodies Market by Source
5.1.1. Murine
5.1.2. Chimeric
5.1.3. Human
5.1.4. Humanized
5.2. Global Monoclonal Antibodies Market by Application
5.2.1. Cancer
5.2.2. Infectious Diseases
5.2.3. Auto-Immune Diseases
5.2.4. Inflammatory Diseases
5.2.5. Others

6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1. AbbVie, Inc.
7.2. Amgen, Inc.
7.3. AstraZeneca plc
7.4. Aytu BioScience, Inc.
7.5. Bayer AG
7.6. Biocon, Ltd.
7.7. Biogen, Inc.
7.8. Bristol Myers Squibb Co.
7.9. Cadila Pharmaceuticals, Ltd.
7.10. Daiichi Sankyo Company, Ltd.
7.11. Dr. Reddy's Laboratories, Inc.
7.12. Eli Lilly and Co.
7.13. F. Hoffmann-La Roche AG
7.14. Genmab A/S
7.15. Gilead Sciences, Inc.
7.16. GlaxoSmithKline plc
7.17. Innate Pharma S.A.
7.18. Intas Biopharmaceuticals, Ltd.
7.19. Johnson & Johnson Services, Inc.
7.20. Lupin, Ltd.
7.21. Merck & Co., Inc.
7.22. Mylan N.V.
7.23. Novartis AG
7.24. Oncologie, Inc.
7.25. Orchard Therapeutics plc
7.26. Pfizer, Inc.
7.27. Sanofi S.A.
7.28. Spectrum Pharmaceuticals, Inc.
7.29. Sun Pharmaceutical Industries, Ltd.
7.30. Takeda Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca plc
  • Aytu BioScience, Inc.
  • Bayer AG
  • Biocon, Ltd.
  • Biogen, Inc.
  • Bristol Myers Squibb Co.
  • Cadila Pharmaceuticals, Ltd.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy's Laboratories, Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Innate Pharma S.A.
  • Intas Biopharmaceuticals, Ltd.
  • Johnson & Johnson Services, Inc.
  • Lupin, Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Oncologie, Inc.
  • Orchard Therapeutics plc
  • Pfizer, Inc.
  • Sanofi S.A.
  • Spectrum Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries, Ltd.
  • Takeda Pharmaceutical Co., Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll